Metabolic Disorders · Oral Therapy
The ongoing clinical trial for BI 764198 is critical as it evaluates safety and pharmacokinetics, which are essential for its future market positioning. Positive outcomes could enhance Boehringer Ingelheim's competitive edge in the metabolic disorders therapeutic area.
Explore aggregated signals, assets, and competitive context for organizations linked to this signal.
Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.
Last run 7/21/2026, 6:02:38 AM
Assessment confidence: 58% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.
The ongoing clinical trial for BI 764198 is critical as it evaluates safety and pharmacokinetics, which are essential for its future market positioning. Positive outcomes could enhance Boehringer Ingelheim's competitive edge in the metabolic disorders therapeutic area. Regulatory context from FDA (FDA’s approval of Veklury (remdesivir) for the treatment of COVID-19—the science of safety and effectiveness) supports the near-term read. Assessment grounded in 15 ranked evidence items (4 high-relevance).
Portfolio teams should monitor the outcomes of this trial to gauge the viability of BI 764198 as a potential treatment option and its market entry strategy. The strongest clinical anchor is Long-Term Real-World Evidence Study to Evaluate Effectiveness, Persistence, Adherence, Safety and Tolerability of Long-acting Cabotegravir Plus Rilpivirine. In Metabolic Disorders · Oral Therapy, 5 regulatory and 1 competitive items passed relevance filtering for Boehringer Ingelheim.
The most relevant competitive pressure comes from Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study (Humanexa Signals) — sponsor/company relevance (roche). This trial could provide insights into the safety profile and dosing strategy for BI 764198, impacting its competitive positioning in the metabolic disorders space.
Regulatory risk is concentrated around FDA’s approval of Veklury (remdesivir) for the treatment of COVID-19—the science of safety and effectiveness (FDA). Regulatory pathway relevance (approval). Relevant agencies in corpus: FDA, MHRA. The safety and tolerability data from this trial will be pivotal for regulatory submissions and could affect the approval timeline for BI 764198.
FDA’s approval of Veklury (remdesivir) for the treatment of COVID-19—the science of safety and effectiveness
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View sourceClinical trials for medicines: collection, verification and reporting of safety events
MHRAmedium relevance
Moderate corpus alignment
FDA document
View sourceOffice of New Drugs Custom Medical Queries (OCMQs) for Safety Signal Detection in Clinical Trial Data - 06/23/2026
FDAmedium relevance
Moderate corpus alignment
FDA document
View sourceField Safety Notices: 6 to 10 July 2026
MHRAmedium relevance
Moderate corpus alignment
FDA document
View sourceField Safety Notices: 22 to 26 June 2026
MHRAmedium relevance
Moderate corpus alignment
FDA document
View sourceLong-Term Real-World Evidence Study to Evaluate Effectiveness, Persistence, Adherence, Safety and Tolerability of Long-acting Cabotegravir Plus Rilpivirine.
ClinicalTrials.govhigh relevance
Mechanism alignment (IO )
FDA document
View sourceStudy to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View sourceA Safety, Tolerability and Levodopa Pharmacokinetics Study of Repeated ND0612 in Parkinson's Disease Patients
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceSafety, PK/PD (Pharmacokinetics/Pharmacodynamics) and Efficacy of ACP-001 Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceA Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceRoche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Safety, tolerability, pharmacokinetics, and pharmacodynamics of oral JMKX003002 in Chinese healthy participants: a randomized, double-blind, placebo-controlled, single- and multiple-ascending dose, an
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceEfficacy and safety of oral finasteride versus dutasteride in moderate-to-severe androgenetic alopecia in males based on trichoscopic and laboratory findings: a clinical comparison in Iran.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceEffects of intraoperative low-dose remimazolam maintenance on emergence agitation and emergence time in patients undergoing oral surgery: protocol for a randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceTransdermal versus oral hormone replacement therapy and bone mass density in Turner syndrome patients: a pilot study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourcePrecedents · guidance
Loading regulatory precedents…
View full regulatory analysisCompetitors · threats
Loading competitive findings…
View full competitive analysisThe ongoing clinical trial for BI 764198 is critical as it evaluates safety and pharmacokinetics, which are essential for its future market positioning. Positive outcomes could enhance Boehringer Ingelheim's competitive edge in the metabolic disorders therapeutic area.
The trial results will influence the market entry strategy and potential revenue generation for BI 764198, impacting Boehringer Ingelheim's market share in metabolic disorders.
The safety and tolerability data from this trial will be pivotal for regulatory submissions and could affect the approval timeline for BI 764198.
Key milestones include the trial completion date and results publication, which will inform on safety and dosing recommendations.
Track for follow-up milestones; no immediate action required.